MENU
Go to the list of all blogs
Allana's Avatar
published in Blogs
Jan 21, 2019

Glaxo Chairman Hampton to Leave

Philip Hampton, Chairman of GlaxoSmithKline, is stepping down from the company only a month after the company announced a merger with Pfizer.

The pharmaceutical giant said on Monday that Mr Hampton, who was appointed non-executive chairman in 2015, has “informed the board of his intention to step down” and the search for his successor has begun. No date for Mr Hampton’s departure was given. Under terms of the all-share deal, Glaxo will own 68% of the consumer healthcare joint venture, while US firm Pfizer will own the remaining 32% stake.

Related Ticker: GSK

GSK in upward trend: price rose above 50-day moving average on July 09, 2025

GSK moved above its 50-day moving average on July 09, 2025 date and that indicates a change from a downward trend to an upward trend. In of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where GSK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 07, 2025. You may want to consider a long position or call options on GSK as a result. In of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GSK advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 233 cases where GSK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for GSK moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for GSK turned negative on June 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 10-day moving average for GSK crossed bearishly below the 50-day moving average on July 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GSK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

GSK broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.144) is normal, around the industry mean (5.632). P/E Ratio (14.012) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (1.126) is also within normal values, averaging (3.004). Dividend Yield (0.035) settles around the average of (0.161) among similar stocks. P/S Ratio (2.277) is also within normal values, averaging (3.643).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GSK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock slightly better than average.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 86.34B. The market cap for tickers in the group ranges from 72.83K to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 11%. OPHLF experienced the highest price growth at 16%, while SNPHY experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -7%. For the same stocks of the Industry, the average monthly volume growth was 9% and the average quarterly volume growth was 12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 33
P/E Growth Rating: 72
Price Growth Rating: 54
SMR Rating: 58
Profit Risk Rating: 79
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of vaccines and other pharmaceutical products

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
980 Great West Road
Phone
+44 2080475000
Employees
70212
Web
https://www.gsk.com